Carriage of 3GCREB in patients at risk for relapsing infection: randomized controlled trial of intestinal decolonization with colistin plus rifaximin.

Trial Profile

Carriage of 3GCREB in patients at risk for relapsing infection: randomized controlled trial of intestinal decolonization with colistin plus rifaximin.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Colistin (Primary) ; Rifaximin (Primary)
  • Indications Enterobacteriaceae infections
  • Focus Therapeutic Use
  • Acronyms Eradicate
  • Most Recent Events

    • 16 Mar 2017 Status changed from suspended to discontinued.
    • 28 Dec 2016 Status changed from recruiting to suspended.
    • 29 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top